Latest:
Back to Basics Slide Deck Resource
Through a series of case studies, the second Back to Basics downloadable, state-of-the-art slide deck, Elevated Lp(a): Who is at risk?, considers the non-modifiable and modifiable risk factors for elevated Lp(a) and the evidence supporting these associations, together with the guidelines-based cardiovascular risk management recommendations for patients in these high risk groups.
In her accompanying expert video commentary, Lp(a) Forum Editorial Advisory Board Member, Dr Jaimini Cegla, expands on these important issues in clinical practice.
Lilly has provided arms’ length sponsorship funding for the Lp(a) Forum Back to Basics Educational Resources but has had no influence or control over the content.
Latest Congress Highlights
Among the Lp(a) research highlights, presented at the American Heart Association Scientific Sessions 2025 (7-10 November, New Orleans), were a further analysis of data from the Phase 2 OCEAN(a)-DOSE study and new insights into the role of Lp(a) in myocardial inflammation, opportunities to address barriers to Lp(a) clinical trial recruitment, projections on the impact of Lp(a) lowering on coronary heart disease risk, and the potential effects of social deprivation on epigenetic modification of the LPA gene and changes in plasma Lp(a) levels.
Second Closed Scientific Expert Meeting of the Editorial Board
Update on Phase 2/3 investigations of lepodisiran and muvalaplin
Professor Steve Nissen, Cleveland Clinic, Ohio, USA, presents results of the ALPACA trial with lepodisiran and the KRAKEN trial of muvalaplin in patients with elevated Lp(a).
Update on the olpasiran clinical development programme
Professor Michelle O’Donoghue, Brigham and Women’s Hospital, Boston, USA, presents data from the Phase 2 OCEAN(a)-DOSE trial and previews the OCEAN(a)-OUTCOMES study.
Lp(a)HORIZON cardiovascular
outcome trial
Professor Steve Nissen, Cleveland Clinic, Ohio, USA, provides an update of the Lp(a)HORIZON trial – the first study due to report results of Lp(a) reduction on cardiovascular outcomes.
Elevated Lp(a) and coronary artery disease severity
Professor Ulf Landmesser, Charité University Medicine Berlin, Germany, presents research linking higher Lp(a) levels with more severe and complex-to-treat coronary artery disease.
About Lp(a) Forum
The Lp(a) Forum is a new, independent, non-profit, expert-led, global initiative providing clinicians and researchers worldwide with open access, peer-reviewed resources devoted to the exciting and rapidly developing area of Lp(a) science and therapeutics.
The Forum brings together internationally-recognised experts from the scientific and clinical communities who are committed to developing awareness, knowledge and understanding of the importance of Lp(a) as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, even when LDL-cholesterol levels are low… Read more
Free Membership
Lp(a) Forum Co-Chair, Professor John Chapman, invites you to join Lp(a) Forum for open access to multimedia educational resources about Lp(a) science, management and research.
Why do we need this Forum?
In recent years, unequivocal evidence has been published supporting Lp(a) as a target for lipid lowering therapies to reduce cardiovascular risk in individuals with significantly elevated Lp(a) levels. Innovative Lp(a) targeted therapies are in development and there is now an urgent need for reliable, accessible scientific and clinical information about Lp(a) for the clinical and scientific community that is appropriate for all levels of expertise and interest.
Lp(a) Forum Co-Chair, Professor John Chapman, turns the spotlight on the accumulating observational, genetic and mechanistic evidence supporting Lp(a) as an independent, causal risk factor for cardiovascular disease, and discusses the promise of novel Lp(a)-lowering agents in development.
Lp(a) Forum Co-Chair, Professor Henry Ginsberg, explains why the time is right to focus on Lp(a) as an important risk factor for cardiovascular disease and to ensure that current knowledge and news of future advances are accessible to clinicians and researchers worldwide.
Expert Views
High risk patients: Breaking down barriers to evidence-based care
Professor Keith Ferdinand, Tulane University School of Medicine, New Orleans, USA, discusses how people of African, South Asian and Hispanic descent typically have higher levels of Lp(a) and more ASCVD risk, yet often miss out on essential healthcare interventions.
Clinical trials targeting Lp(a) – What’s new?
Professor Ioanna Gouni-Berthold, University of Cologne, Germany, discusses recently published and ongoing studies of antisense oligonucleotides, small interfering RNAs and small molecules targeting Lp(a).
Research highlights since Lp(a) Forum launch
Dr Elias Björnson, University of Gothenburg, Sweden, discusses some memorable scientific advances and clinical developments in the field of Lp(a) research and looks forward to further investigations.
The importance of Lp(a) testing
Professor Keith Ferdinand, Tulane University School of Medicine, New Orleans, USA, highlights the importance of testing Lp(a) levels.
Lp(a) and coronary plaque progression
Professor Marc Dweck, University of Edinburgh, UK, reports recent imaging research that links Lp(a) to progression of the most unstable coronary plaques.
Slides
Lp(a): A new causal risk factor for ASCVD and aortic valve stenosis
Download this topical introductory slide deck to Lp(a), developed by Lp(a) Forum Co-Chair, Professor John Chapman, which summarises key evidence supporting the role of Lp(a) as a causal risk factor in cardiovascular disease
Trials
Multiple Lp(a) targeted therapeutics are undergoing extensive clinical trials to investigate their safety, efficacy and tolerability, and potential benefits for cardiovascular outcomes.
Video Library
International experts discuss hot topics on all aspects of the epidemiology, genetics and pathophysiology of Lp(a).
Lp(a): What do the guidelines say?
Multiple expert guidelines recognise Lp(a) as a risk factor for cardiovascular disease and advise on Lp(a) measurement and treatment as part of broader risk management…
Back to Basics
Back to Basics summarises current thinking on key aspects of Lp(a) science and management
What is Lp(a)
Lp(a) is a plasma lipoprotein that consists of an LDL-like particle in which apolipoprotein B100 is covalently linked to the plasminogen-like protein…
Read more
Lp(a) measurement
Lp(a) level is measured as Lp(a) particle number (nmol/L) or Lp(a) mass concentration (mg/dL), and levels ≥100/125 nmol/L (≥50 mg/dL) are …
Read more
Why test Lp(a)?
Professor Keith Ferdinand, Tulane University School of Medicine, New Orleans, USA, discusses the advantages of Lp(a) testing for patients and their families…
Read more
Lp(a) and CVD
Elevated Lp(a) is associated with increased risk of coronary heart disease, ischaemic stroke, peripheral artery disease, heart failure, aortic stenosis and mortality …
Read more
Lp(a) therapies
No Lp(a) targeted therapies have been approved, but experts agree that intensive management of other risk factors is important in individuals with elevated …
Read more
News
Practical framework for Lp(a) screening and CV risk reduction in Canada
A practical framework for Lp(a) screening and cardiovascular (CV) risk assessment and management in Canada highlights inconsistent Lp(a) …
OxPL-apoB and OxPL-apo(a) tests validated for potential use in Lp(a) studies
Chemiluminescent ELISA methods for analysing the oxidised phospholipids, OxPL-apoB and OxPL-apo(a), have been validated …
Lp(a) perceptions in Latin America
Awareness of the importance of Lp(a) testing is limited among Latin American (LATAM) physicians and focused on high risk …
2025 – A Year of New Insights in Lp(a) Science
As 2025 comes to a close, we’re reflecting on a year of important scientific advances and encouraging clinical insights …
Major Lp(a) changes mainly due to technical issues
Major Lp(a) changes are due mainly to technical issues rather than biological fluctuations, according to results of a study, …
Other Congress News
ESC Congress 2025
29 August – 1 September, Madrid, Spain
At a record breaking ESC 2025, with over 1,100 sessions showcasing practice-changing research, Lp(a) focused advances included new ESC/EAS guidance on Lp(a) as a cardiovascular risk-enhancing factor, together with new research on reduced need for lipoprotein apheresis with Lp(a) lowering therapy, latest trends in Lp(a) testing, patient advice about Lp(a), and further evidence linking elevated Lp(a) with poor cardiovascular outcomes.
Upcoming Congress
ACC.26
28 – 30 March, New Orleans, USA
